Systematic benchmarking shows existing transcriptomic predictors for immune checkpoint inhibitor response have limited cross-cohort generalisability and inconsistent biomarker signals.
Microsatellite- Stable Tumors with High Mutational Burden Benefit from Immunotherapy
1 Pith paper cite this work. Polarity classification is still indexing.
1
Pith paper citing it
fields
q-bio.GN 1years
2026 1verdicts
UNVERDICTED 1representative citing papers
citing papers explorer
-
Transcriptomic Models for Immunotherapy Response Prediction Show Limited Cross-cohort Generalisability
Systematic benchmarking shows existing transcriptomic predictors for immune checkpoint inhibitor response have limited cross-cohort generalisability and inconsistent biomarker signals.